Related Experiment Video
Updated: May 16, 2026
10:38
In Vivo Alkaline Comet Assay and Enzyme-modified Alkaline Comet Assay for Measuring DNA Strand Breaks and Oxidative DNA Damage in Rat Liver
Published on: May 4, 2016
16.3K
Medical Device Regulation - Who Does the FDA Serve?
1Department of Medicine, https://ror.org/00f54p054Stanford University, United States.
Summary
Political and institutional factors create a reactive regulatory system favoring industry over public health. Fundamental reforms are needed to prioritize patient and public well-being in device regulation.
Area of Science:
- Public Health Policy
- Regulatory Science
- Health Law
Background:
- Current medical device regulation is characterized by a reactive approach.
- This system is influenced by political pressures and institutional constraints.
- Existing frameworks often prioritize industry interests above public health concerns.
Purpose of the Study:
- To analyze the systemic issues within current medical device regulatory frameworks.
- To identify the need for reforms beyond incremental or technical adjustments.
- To advocate for a foundational shift in regulatory values to better serve patients and public health.
Main Methods:
- Qualitative analysis of regulatory policy documents.
- Review of legislative history and institutional frameworks.
- Comparative analysis of regulatory outcomes and public health impact.
Main Results:
- The regulatory system exhibits a reactionary pattern, influenced by political and institutional dynamics.
- Industry interests are disproportionately favored over public health considerations.
- Standard reforms are insufficient to address the deep-seated issues in device regulation.
Conclusions:
- Breaking the cycle of reactive regulation requires fundamental value-based reforms.
- Revisiting foundational principles of device regulation is essential.
- Policy alignment with patient and public health interests necessitates a paradigm shift.
Related Concept Videos
01:25Drug Regulation
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
01:19Pharmacovigilance
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
01:03Drug Control Governance: Regulatory Bodies and Their Impact
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with a...
01:13Bioequivalence studies: Biowaivers
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
01:28Drug Products: Biologics, Biosimilars and Interchangeables
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
01:26FDA Approved Drugs: Changes to Approved Drugs
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...